TL;DR
New Haven anchors the Connecticut biotech cluster centered on Yale University and Yale School of Medicine spinouts, Science Park incubator operators, and the broader BioCT operator network. The cluster has a strong oncology, immunology, and rare disease focus with insurance characteristics combining standard clinical-stage biotech architecture with CTDPA cyber overlay and a relatively lighter securities posture than coastal hub markets.
New Haven biotech
New Haven biotech insurance - Yale spinouts, Science Park, BioCT operators.
New Haven is the center of the Connecticut biotech cluster, anchored by Yale University and Yale School of Medicine - one of the leading US biomedical research universities. The cluster has been substantially built out by Yale spinouts across oncology, immunology, neuroscience, and rare disease programs, plus the Science Park incubator infrastructure and the broader BioCT network.
Cluster characteristics
Yale spinouts dominate the cluster shape.
Yale University and Yale School of Medicine spinouts operate across oncology, immunology, neuroscience, rare disease, and infectious disease programs. Yale Ventures licensing structures are notably active and produce distinctive indemnity considerations in spinout MSAs.
Science Park incubator operators run lean insurance programs at pre-IND stage, scaling as funding rounds close.
BioCT operator network spans clinical-stage biotech, biopharmaceutical services, and adjacent operators across Connecticut. The network anchors at the New Haven, Branford, and Groton sub-clusters.
New Haven biotech coverage review